The BCL9L (B-cell lymphoma 9-like) protein is a key regulatory component of the Wnt/β-catenin signaling pathway, which plays critical roles in embryonic development, tissue homeostasis, and cancer progression. BCL9L, along with its homolog BCL9. acts as a transcriptional coactivator by facilitating the nuclear translocation of β-catenin and enhancing its interaction with TCF/LEF transcription factors to drive target gene expression. Dysregulation of this pathway, particularly through BCL9L overexpression or mutations, has been implicated in various cancers, including colorectal, hepatocellular, and hematological malignancies.
BCL9L-specific antibodies are essential tools for studying its expression, localization, and functional interactions in both physiological and pathological contexts. These antibodies are widely used in techniques such as Western blotting, immunohistochemistry, and immunoprecipitation to investigate BCL9L’s role in tumorigenesis and metastasis. Research has highlighted BCL9L as a potential therapeutic target, as its inhibition can disrupt β-catenin-dependent oncogenic signaling without severely affecting normal Wnt pathway functions. Additionally, studies using BCL9L antibodies have explored its involvement in immune modulation and stem cell maintenance, underscoring its multifaceted contributions to disease mechanisms. The development of selective BCL9L antibodies continues to advance precision oncology efforts, particularly in cancers driven by Wnt pathway hyperactivity.